Miyako Satouchi
Akashi, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 113 publications
Development of Therapies Targeting Non-G12C KRAS Mutations (Focusing on G12D and Pan-RAS)
Journal: Gan to kagaku ryoho. Cancer & chemotherapy
Published: August 04, 2026
Response to "Reconsidering 'photon-ineligible' status in concurrent chemo-proton therapy for stage III non-small cell lung cancer".
Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Published: June 14, 2026
Successful Rechallenge of Trastuzumab Deruxtecan Following Early Detection of ILD in a Patient with Non-small Cell Lung Carcinoma Harboring HER2 Exon 20 Insertion.
Journal: Internal medicine (Tokyo, Japan)
Published: November 05, 2025
RELAY: safety and efficacy of ramucirumab plus erlotinib in elderly Japanese patients with metastatic EGFR-mutated NSCLC.
Journal: Future oncology (London, England)
Published: September 25, 2025
Successful Tepotinib Rechallenge after Tepotinib-induced Adverse Events Following Pembrolizumab Failure in a Case of Non-small Cell Lung Carcinoma with MET Exon 14 Skipping.
Journal: Internal medicine (Tokyo, Japan)
Published: September 24, 2025
Biomarker analyses to predict benefit of immune checkpoint inhibitors for EGFR-mutated non-small cell lung cancer.
Journal: Cancer treatment and research communications
Published: August 21, 2025
Long-term outcomes of concurrent chemo-proton therapy for unresectable stage III non-small cell lung cancer: a Japanese national registry study.
Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Published: July 13, 2025
Carbon-Ion radiotherapy alone for inoperable locally advanced Non-Small cell lung cancer: A Japanese National registry study (J-CROS-LUNG).
Journal: Japanese journal of radiology
Published: June 24, 2025
RELAY+: Final Overall Survival With Ramucirumab Plus Gefitinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC.
Journal: JTO clinical and research reports
Published: May 20, 2025
Final Survival Outcomes With Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC: RELAY Japanese Subset.
Journal: JTO clinical and research reports
Published: December 19, 2024
Clinical outcomes of proton beam therapy for inoperable stage I-IIA non-small cell lung cancer: Japanese nationwide registry study.
Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Published: November 17, 2024
Current Status and Issues of Companion Diagnostics for Non-Small Cell Lung Cancer
Journal: Gan to kagaku ryoho. Cancer & chemotherapy
Published: April 21, 2024
Last Updated: 09/26/2026